BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18256529)

  • 1. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.
    Hancock JD; Lessnick SL
    Cell Cycle; 2008 Jan; 7(2):250-6. PubMed ID: 18256529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
    Owen LA; Kowalewski AA; Lessnick SL
    PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.
    Braunreiter CL; Hancock JD; Coffin CM; Boucher KM; Lessnick SL
    Cell Cycle; 2006 Dec; 5(23):2753-9. PubMed ID: 17172842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.
    Smith R; Owen LA; Trem DJ; Wong JS; Whangbo JS; Golub TR; Lessnick SL
    Cancer Cell; 2006 May; 9(5):405-16. PubMed ID: 16697960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellites as EWS/FLI response elements in Ewing's sarcoma.
    Gangwal K; Sankar S; Hollenhorst PC; Kinsey M; Haroldsen SC; Shah AA; Boucher KM; Watkins WS; Jorde LB; Graves BJ; Lessnick SL
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10149-54. PubMed ID: 18626011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promiscuous partnerships in Ewing's sarcoma.
    Sankar S; Lessnick SL
    Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
    Prieur A; Tirode F; Cohen P; Delattre O
    Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure.
    Gangwal K; Lessnick SL
    Cell Cycle; 2008 Oct; 7(20):3127-32. PubMed ID: 18927503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.
    De Vito C; Riggi N; Suvà ML; Janiszewska M; Horlbeck J; Baumer K; Provero P; Stamenkovic I
    PLoS One; 2011; 6(8):e23592. PubMed ID: 21853155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
    Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma.
    Owen LA; Lessnick SL
    Cell Cycle; 2006 Sep; 5(18):2049-53. PubMed ID: 16969112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
    Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
    Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.
    Lessnick SL; Dacwag CS; Golub TR
    Cancer Cell; 2002 May; 1(4):393-401. PubMed ID: 12086853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
    Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
    Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ewing's sarcoma: general insights from a rare model.
    Davis S; Meltzer PS
    Cancer Cell; 2006 May; 9(5):331-2. PubMed ID: 16697953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro.
    Chansky HA; Barahmand-Pour F; Mei Q; Kahn-Farooqi W; Zielinska-Kwiatkowska A; Blackburn M; Chansky K; Conrad EU; Bruckner JD; Greenlee TK; Yang L
    J Orthop Res; 2004 Jul; 22(4):910-7. PubMed ID: 15183454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma.
    Eliazer S; Spencer J; Ye D; Olson E; Ilaria RL
    Mol Cell Biol; 2003 Jan; 23(2):482-92. PubMed ID: 12509448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.